PCCW Limited (FRA:TH3B)
0.6250
0.00 (0.00%)
Last updated: Jul 31, 2025
Intra-Cellular Therapies Revenue
In the year 2024, PCCW Limited had annual revenue of 37.56B HKD with 3.33% growth. PCCW Limited had revenue of 19.86B in the half year ending December 31, 2024, with 2.75% growth.
Revenue
37.56B HKD
Revenue Growth
+3.33%
P/S Ratio
1.14
Revenue / Employee
2.57M HKD
Employees
14,600
Market Cap
4.79B USD
Revenue Chart
* This company reports financials in HKD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 37.56B | 1.21B | 3.33% |
Dec 31, 2023 | 36.35B | 282.00M | 0.78% |
Dec 31, 2022 | 36.07B | 610.00M | 1.72% |
Dec 31, 2021 | 35.46B | -529.00M | -1.47% |
Dec 31, 2020 | 35.98B | -1.54B | -4.10% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 77.82B |
Deutsche Telekom AG | 120.25B |
Allianz SE | 109.03B |
Siemens Energy AG | 37.44B |
Rheinmetall AG | 10.48B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
Deutsche Bank Aktiengesellschaft | 30.07B |